Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Stelazine. Every FDA application for this active ingredient: 1 branded and 21 generic.
As of Nov 15, 2026, FDA lists 22 applications for Trifluoperazine Hydrochloride (sold as Stelazine), first approved Apr 16, 1959, with 0 new uses approved and 0 published complete response letters.
First approved: Apr 16, 1959
Applications: 22
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $2.0M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Trifluoperazine HCl
Part D
$2.0M
-8%
5,512
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
TRIFLUOPERAZINE 1 MG TABLET: $0.405 per unitGeneric · -2% in a year
TRIFLUOPERAZINE 10 MG TABLET: $1.24 per unitGeneric · -10% in a year
TRIFLUOPERAZINE 2 MG TABLET: $0.535 per unitGeneric · -19% in a year
TRIFLUOPERAZINE 5 MG TABLET: $0.756 per unitGeneric · +6% in a year
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Glaxosmithkline
Sandoz
Wockhardt
Mylan